Skip to main content
GENFIT logo

GENFIT — Investor Relations & Filings

Ticker · GNFT ISIN · FR0004163111 LEI · 969500XPWN2DMZQA5X73 PA Professional, scientific and technical activities
Open in API
Filings indexed 681 across all filing types
Latest filing 2016-11-10 Regulatory Filings
Country FR France
Listing PA GNFT

About GENFIT

https://www.genfit.com

GENFIT is a biopharmaceutical company dedicated to developing therapeutic and diagnostic solutions for patients with rare and severe liver diseases characterized by high unmet medical needs. The company's primary focus is on Acute-on-Chronic Liver Failure (ACLF) and its associated conditions, such as acute decompensation (AD) and hepatic encephalopathy (HE). Leveraging a scientific heritage of over two decades, GENFIT is a pioneer in liver disease research and development, aiming to improve the lives of patients with these life-threatening conditions.

Recent filings

Filing Released Lang Actions
2016.11.10 CP GENFIT NASH Registry Project
Regulatory Filings Classification · 97% confidence The document is a press release dated November 10, 2016, announcing a long-term agreement between GENFIT and the Pinnacle Research Center regarding a NASH Registry Project. It details a business development/research collaboration and also mentions upcoming presentations and webcasts at the AASLD 2016 conference. This type of announcement, which details strategic partnerships, research updates, and upcoming investor events (like webcasts), is characteristic of general corporate news releases intended for investors and the public. It is not a formal regulatory filing like a 10-K, a specific financial report like an IR or ER, or a proxy statement. Since it is a general corporate announcement detailing business activities and future events, it fits best under the 'Regulatory Filings' (RNS) category as a general regulatory/corporate disclosure, or potentially an Investor Presentation (IP) if it were the presentation itself, but here it is the announcement *about* the research and the upcoming presentation/webcast. Given the content is a press release announcing a partnership and upcoming conference participation, RNS (Regulatory Filings/General Announcement) is the most appropriate general classification when a more specific category like 'IP' (Investor Presentation) or 'ER' (Earnings Release) does not perfectly match the format or primary purpose. However, since it is a detailed announcement of strategic business developments and research progress, it often falls under the broader category of investor relations material. Given the options, and that it is a formal press release detailing strategic moves, RNS serves as the best fit for a non-standard, non-periodic disclosure.
2016-11-10 French
2016.11.10 PR GENFIT NASH Registry Project
Regulatory Filings Classification · 95% confidence The document is a press release dated November 10, 2016, announcing a new agreement for a NASH Registry Project and providing updates on GENFIT's participation and presentations at the 2016 AASLD Annual Meeting, including webcast details. It contains business updates, scientific information, and forward-looking statements, typical of a corporate announcement intended for investors and the public. It is not a formal regulatory filing like a 10-K, a comprehensive quarterly report (IR), or a specific financial event report (like DIV or CAP). Since it announces business developments and provides context for upcoming investor events (webcast/presentations), it fits best under the general category of corporate news or investor relations material. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general corporate press release that doesn't fit a more specific category like ER, CT, or IP, although it shares characteristics with an Investor Presentation (IP) or Earnings Release (ER) in its intent to communicate news. However, as it is primarily a press release announcing a partnership and upcoming conference activities, RNS serves as the best general classification for non-standard, material corporate news announcements.
2016-11-10 English
2016.11.04 CP GENFIT PBC FDA clearance
Earnings Release Classification · 95% confidence The document is explicitly titled 'COMMUNIQUÉ DE PRESSE' (Press Release) multiple times. It announces a specific corporate event: the official approval by the FDA (Food and Drug Administration) of an Investigational New Drug (IND) application for a Phase II clinical trial for the drug elafibranor in treating Primary Biliary Cholangitis (PBC). This type of announcement, detailing regulatory milestones, clinical trial progress, and corporate news, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a formal announcement of a significant regulatory event (IND approval) rather than a comprehensive financial report (like 10-K or IR) or a transcript (CT), it fits best under the 'Earnings Release' category if it contains key financial/operational highlights, or 'Regulatory Filings' if it's purely regulatory news. Given the focus is on a regulatory/clinical milestone announcement, and it is not a full financial report, 'ER' (Earnings Release) is often used for major operational updates accompanying financial periods, but 'RNS' (Regulatory Filings) is a strong candidate for specific regulatory news. However, press releases announcing key operational/regulatory achievements are frequently categorized as ERs in many databases, especially when they are not explicitly a 'Report Publication Announcement' (RPA). Since this is a major, time-sensitive announcement about FDA action, it functions as a key operational update. I will classify it as ER, as it is a formal press release announcing a significant operational/regulatory milestone, which often accompanies or substitutes for a formal earnings report announcement in terms of market impact, though RNS is also plausible. Given the options, ER captures the nature of a major, time-sensitive corporate announcement better than the generic RNS, unless it was purely administrative. The document length (7168 chars) is substantial enough to be more than a brief notification. FY 2016
2016-11-04 French
2016.11.04 PR GENFIT PBC FDA clearance
Regulatory Filings Classification · 95% confidence The document is explicitly titled 'PRESS RELEASE' multiple times and announces a specific corporate event: the FDA clearing an Investigational New Drug (IND) application for a Phase II trial. This type of announcement, detailing clinical trial progress, regulatory milestones, and providing company/product background, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a formal press release announcing a significant operational/regulatory update rather than a comprehensive financial report (like 10-K or IR) or a transcript (CT), the best fit among the specific options is 'Earnings Release' (ER) if it were tied to a reporting period, or 'Regulatory Filing' (RNS) as a general announcement. Given the content focuses heavily on clinical/regulatory progress rather than quarterly financial results highlights, and it is a standard press release format, 'RNS' (Regulatory Filings - general regulatory announcements) is the most appropriate fallback, although 'ER' often covers major operational news too. However, since it is a press release announcing a specific regulatory clearance, and not a summary of financial performance, RNS is safer, or potentially IP if it were an investor presentation, but it is clearly a press release. I will classify it as RNS as it is a general regulatory announcement/press release that doesn't fit the other specific categories well.
2016-11-04 English
2016.10.31 CP GENFIT Resultats AK DPS
Share Issue/Capital Change Classification · 99% confidence The document is a press release announcing the 'TRES LARGE SUCCES DE L'AUGMENTATION DE CAPITAL' (Very Large Success of the Capital Increase) for GENFIT, detailing the total demand, subscription rate, and the total amount raised (approximately 78.5 million euros). This content directly relates to fundraising, financing activities, and capital structure changes. This aligns perfectly with the definition for 'Capital/Financing Update' (Code: CAP). Although it mentions a prospectus was approved by the AMF, the document itself is the announcement of the successful completion of the capital raise, not the prospectus or the final report itself.
2016-10-31 French
2016.10.31 PR GENFIT Results RI
Share Issue/Capital Change Classification · 99% confidence The document is a press release announcing the 'success of the share capital increase with shareholders' preferential subscription rights (the "Rights Offering")' and detailing the total demand, subscription rate, and gross amount raised (€78.5 million). This clearly relates to a company fundraising or capital structure change event. Reviewing the definitions, the 'Capital/Financing Update' (CAP) category fits best as it covers 'Updates on company fundraising, financing activities, or capital structure changes.' It is not an Earnings Release (ER), Interim Report (IR), or a formal regulatory filing like a 10-K. The document is substantial and describes the event itself, not just announcing the publication of a separate report.
2016-10-31 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.